Alzheimer's disease (AD) is the most common form of dementia in the elderly. Over the past
20 years, both pharmacological and lifestyle interventions have been studied for AD …

Abstract Aims β-Secretase 1 (BACE1) is a key enzyme in Alzheimer's disease pathogenesis
that catalyses the amyloidogenic cleavage of amyloid precursor protein (APP). Recently …

One of the major breakthroughs in Alzheimer's disease (AD) clinical research over the past
two decades has been the validation of diagnostic biomarkers able to demonstrate the …

Two new sets of criteria for Alzheimer's disease (AD) are now in play, including one set
released in 2014, and a proposal for a “new lexicon” for how to describe the disease …

Background According to new diagnostic guidelines for Alzheimer's disease (AD),
biomarkers enable estimation of the individual likelihood of underlying AD pathophysiology …

Almost 36 million persons live with dementia worldwide. This figure is set to double by 2030,
with 66 million patients, and by 2050 there will be 116 million affected persons. Dementia …

Background: Recent criteria allow biomarkers to provide evidence of Alzheimer's disease
(AD) pathophysiology. How they should be implemented in daily practice remains unclear …

Deux nouvelles séries de critères pour le diagnostic de la maladie d'Alzheimer sont
maintenant en vigueur, incluant une série publiée en 2014. Un «nouveau lexique» …

The aim of this study was to examine the relationship between cerebrospinal fluid (CSF)
levels of biomarkers for Alzheimer's disease (AD)(Aß1–42, t-tau, and p-tau) and …

Background In the primary care setting, dementia is often diagnosed relatively late in the
disease process. Case finding and proactive collaborative care may have beneficial effects …